HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lech-Maranda, E. Articles by Robak, T. Search for Related Content PubMed PubMed Citation Articles by Lech-Maranda, E. Articles by Robak, T.

Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia

^* Department of Hematology, Medical University of Lodz, Poland
^° Department of Pharmaceutical Biochemistry, Medical University of Lodz, Poland

Correspondence: Tadeusz Robak, MD, PhD, Department of Hematology, Medical University of Lodz, Ciolkowskiego 2 str, 93-510 Lodz, Poland. Phone/fax: international +4842.6895191/6895192. E-mail: robaktad{at}csk.umed.lodz.pl

We investigated HLA DRB1 correlations with chronic lymphocytic leukemia (B-CLL) outcome in 90 patients. Neither of the alleles was associated with B-CLL clinical characteristics or mortality. HLA DRB1*01 and HLA DRB1*02-null were associated with shorter overall survival (p=0.007, p=0.002). Our results suggest that HLA-restricted adaptive immunity influences CLL outcome.

Key words: chronic lymphocytic leukemia, HLA class II, HLA DRB1, outcome.